Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, sodium valproate as monotherapy stopped seizures in 50% of epileptic children and was most effective in primary generalized and photosensitive epilepsies with notable side effects.

This review assesses the potential of dutasteride as a promising treatment for ALS due to its reported neuroprotective, antioxidant, and anti-inflammatory effects, but emphasizes that clinical studies are needed for confirmation.

This study highlights that while there are no FDA- or ANVISA-approved treatments for children with alopecia areata, JAK inhibitors are emerging as a promising therapeutic option for this population.

This study observed that serotonin signaling promoted hair shaft elongation and upregulated hair growth-related genes in dermal papilla cells, suggesting its potential role in advancing alopecia therapy.

This study found a significant association between finasteride use and increased risk of memory impairment, highlighting the need for risk communication and routine cognitive monitoring for long-term users.

This study concluded that both finasteride and dutasteride therapies significantly increased chromogranin A serum levels in men with benign prostatic hyperplasia, suggesting an activation of neuroendocrine differentiation.

In this study, a newly designed protein degrader targeting androgen receptors showed promise in reversing hair regrowth inhibition in a mouse model of androgenetic alopecia, suggesting potential as a novel and safe treatment strategy.

Finasteride's effectiveness on the frontal hair loss area is not well-studied or confirmed.

This study found that neonatal administration of finasteride reduced sensitivity to alcohol's motor-stimulating effects and increased preference for novelty and initial alcohol consumption in rats, suggesting a role in alcohol vulnerability.

Finasteride may reduce heart damage in rats.

This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

This case report describes successful treatment of alopecia areata and atopic dermatitis in a pediatric patient using the Janus kinase 1 inhibitor upadacitinib, with significant hair growth improvements noted after six weeks.

In this study, the combination of metoprolol and spironolactone in patients with coronary heart disease and heart failure significantly improved cardiac function and reduced inflammation and oxidative stress markers compared to spironolactone alone, with better clinical efficacy and fewer adverse effects.

This article discusses arsenic trioxide as a treatment for refractory or relapsed acute promyelocytic leukemia, noting its effectiveness and manageable side effects.

This retrospective study found that oral tofacitinib significantly reduced the severity of alopecia areata in children, achieving over a 50% reduction in hair loss severity, though relapse occurred during treatment tapering, and mild adverse effects were noted.

This study explored the development of polymeric nanoparticles for topical spironolactone delivery, finding that larger nanoparticles (180 nm) enhanced drug targeting to hair follicles significantly more than smaller ones or non-nanoparticle formulations, offering promise for safer acne and alopecia treatments.

This study reported that in a case series of three adolescents with alopecia areata and atopic dermatitis, treatment with 15 mg/day of upadacitinib led to rapid improvement in skin symptoms and significant hair regrowth over 12 months, with no severe adverse events observed.

The new topical product combined with finasteride significantly increased hair thickness without side effects.

In this letter, Dr. Mayer Brezis critiques a study on finasteride's mental health impact, arguing that its dismissal of links between the drug and depression or suicide is flawed; he suggests market withdrawal due to established neuropsychiatric risks.

Dutasteride and finasteride have equal safety for treating BPH without increased heart risk.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

This article reviews the characteristics and uses of finasteride for benign prostatic hyperplasia, noting variable symptom improvement and ongoing investigation in other DHT-mediated conditions, and reports no new clinical results.

This study concluded that spironolactone may be an effective therapy for a subgroup of hirsute patients, as it reduced plasma testosterone and improved certain hair growth measures.

This study found that tralokinumab effectively reduced the severity of moderate-to-severe atopic dermatitis over 28 weeks in adults, with significant improvements in clinical outcomes and biological markers, although 27.4% of patients discontinued treatment due to adverse events or ineffectiveness.

This study concluded that 16β-methyl-17α-benzoyloxypregnen-4-en-3,20-dione may be a promising treatment for androgen-dependent diseases and epilepsy due to its antioxidant effects and impact on GABAergic and serotonergic metabolism in rats.

This study reported no significant difference in efficacy or sexual dysfunction risk between 5α-reductase inhibitors and placebo for androgenetic alopecia, suggesting that dutasteride 0.5 mg may be considered pending further research.

In this study, the use of finasteride in young patients may be linked to a higher risk of anxiety, depression, and suicide-related adverse events.

This study found that isotretinoin treatment in adolescents with nodulocystic acne may lead to changes in adrenal hormone levels, and hirsutism and menstrual irregularity can occur during treatment.